Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
8-K
Cytek® Biosciences Names William McCombe Chief Financial Officer
19 Mar 24
S-8
Registration of securities for employees
14 Mar 24
10-K
2023 FY
Annual report
13 Mar 24
NT 10-K
Notice of late annual filing
1 Mar 24
8-K
Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
1 Mar 24
8-K
Departure of Directors or Certain Officers
27 Feb 24
8-K
Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results
9 Jan 24
8-K
Regulation FD Disclosure
28 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
NT 10-Q
Notice of late quarterly filing
13 Nov 23
8-K
Q3 2023 Earnings Call
9 Nov 23
8-K
Cytek Biosciences Reports Third Quarter 2023 Financial Results
7 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Cytek Biosciences Reports Second Quarter 2023 Financial Results
8 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
20 Jun 23
8-K/A
Financial Statements and Exhibits
15 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Cytek Biosciences Reports First Quarter 2023 Financial Results
9 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
S-8
Registration of securities for employees
1 Mar 23
10-K
2022 FY
Annual report
1 Mar 23
8-K
Cytek Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
28 Feb 23
8-K
Completion of Acquisition or Disposition of Assets
28 Feb 23
8-K
Cytek® Biosciencesto Acquire Flow Cytometryand Imaging Businessfrom Diasorin
13 Feb 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
8-K
Cytek Biosciences Reports Third Quarter 2022 Financial Results
9 Nov 22
8-K
Cytek® Biosciences Names Chris Williams Chief Operating Officer
1 Nov 22
S-3ASR
Automatic shelf registration
26 Aug 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
8-K
Cytek Biosciences Reports Second Quarter 2022 Financial Results
10 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
6 Jun 22
10-Q
2022 Q1
Quarterly report
11 May 22
8-K
Cytek Biosciences Reports First Quarter 2022 Financial Results
11 May 22
DEFA14A
Additional proxy soliciting materials
14 Apr 22
DEF 14A
Definitive proxy
14 Apr 22
Latest ownership filings
4
Ming Yan
23 Apr 24
4
Ming Yan
11 Apr 24
144
Notice of proposed sale of securities
9 Apr 24
4
Philippe Busque
21 Mar 24
3
William D. McCombe
20 Mar 24
4
Ming Yan
19 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
4
Ming Yan
13 Mar 24
4
Paul Christopher Williams
13 Mar 24
4
Allen Poirson
13 Mar 24
4
Wenbin Jiang
13 Mar 24
4
Patrik Jeanmonod
13 Mar 24
4
Valerie Barnett
13 Mar 24
4
Ming Yan
8 Mar 24
4
Paul Christopher Williams
8 Mar 24
4
Allen Poirson
8 Mar 24
4
Wenbin Jiang
8 Mar 24
4
Philippe Busque
8 Mar 24
4
Valerie Barnett
8 Mar 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
22 Feb 24
4
Ming Yan
22 Feb 24
4
Paul Christopher Williams
22 Feb 24
4
Wenbin Jiang
22 Feb 24
4
Valerie Barnett
22 Feb 24
4
Patrik Jeanmonod
22 Feb 24
4
Allen Poirson
22 Feb 24
SC 13G/A
HHLR ADVISORS, LTD.
14 Feb 24
SC 13G/A
Yan Ming
14 Feb 24
SC 13G/A
Jiang Wenbin
14 Feb 24
SC 13G
BROWN CAPITAL MANAGEMENT LLC
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BlackRock Inc.
23 Jan 24
4
Patrik Jeanmonod
27 Dec 23
4
Ming Yan
21 Dec 23
144
Notice of proposed sale of securities
19 Dec 23
4
Patrik Jeanmonod
27 Nov 23
4
Ming Yan
27 Nov 23
4
Ming Yan
21 Nov 23
4
Paul Christopher Williams
21 Nov 23
4
Allen Poirson
21 Nov 23